Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders

Guillaume De Nanteuil; Philippe Gloanec; Suzette Beguin; Peter L. A. Giesen; H. Coenraad Hemker; Philippe  Mennecier; Alain  Rupin; Tony J.  Verbeuren

doi:10.1021/jm0606950

Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders

Guillaume De Nanteuil^*, Philippe Gloanec, Suzette Beguin, Peter L. A. Giesen, H. Coenraad Hemker, Philippe Mennecier, Alain Rupin, Tony J. Verbeuren

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

134 Downloads (Pure)

Abstract

The synthesis and evaluation of inhibitors of activated protein C (aPC) are reported. This serine protease is partly responsible for the degradation of factor VIIIa, involved in the regulation of bleeding in hemophilia A. Benzamidine-containing derivatives were found to be potent aPC inhibitors, some of them showing selectivity against the procoagulant protease thrombin. Moreover, compound 1 significantly restored the generation of thrombin in hemophiliac plasma.

Original language	English
Pages (from-to)	5047-5050
Number of pages	4
Journal	Journal of Medicinal Chemistry
Volume	49
Issue number	17
DOIs	https://doi.org/10.1021/jm0606950
Publication status	Published - 25 Jul 2006

Access to Document

10.1021/jm0606950

Full TextFinal published version, 88.3 KB

Cite this

@article{9ffb67f65efb4498bc9e77fb5519a281,

title = "Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders",

abstract = "The synthesis and evaluation of inhibitors of activated protein C (aPC) are reported. This serine protease is partly responsible for the degradation of factor VIIIa, involved in the regulation of bleeding in hemophilia A. Benzamidine-containing derivatives were found to be potent aPC inhibitors, some of them showing selectivity against the procoagulant protease thrombin. Moreover, compound 1 significantly restored the generation of thrombin in hemophiliac plasma.",

author = "{De Nanteuil}, Guillaume and Philippe Gloanec and Suzette Beguin and Giesen, {Peter L. A.} and Hemker, {H. Coenraad} and Philippe Mennecier and Alain Rupin and Verbeuren, {Tony J.}",

year = "2006",

month = jul,

day = "25",

doi = "10.1021/jm0606950",

language = "English",

volume = "49",

pages = "5047--5050",

journal = "Journal of Medicinal Chemistry",

issn = "0022-2623",

publisher = "American Chemical Society",

number = "17",

}

TY - JOUR

T1 - Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders

AU - De Nanteuil, Guillaume

AU - Gloanec, Philippe

AU - Beguin, Suzette

AU - Giesen, Peter L. A.

AU - Hemker, H. Coenraad

AU - Mennecier, Philippe

AU - Rupin, Alain

AU - Verbeuren, Tony J.

PY - 2006/7/25

Y1 - 2006/7/25

N2 - The synthesis and evaluation of inhibitors of activated protein C (aPC) are reported. This serine protease is partly responsible for the degradation of factor VIIIa, involved in the regulation of bleeding in hemophilia A. Benzamidine-containing derivatives were found to be potent aPC inhibitors, some of them showing selectivity against the procoagulant protease thrombin. Moreover, compound 1 significantly restored the generation of thrombin in hemophiliac plasma.

AB - The synthesis and evaluation of inhibitors of activated protein C (aPC) are reported. This serine protease is partly responsible for the degradation of factor VIIIa, involved in the regulation of bleeding in hemophilia A. Benzamidine-containing derivatives were found to be potent aPC inhibitors, some of them showing selectivity against the procoagulant protease thrombin. Moreover, compound 1 significantly restored the generation of thrombin in hemophiliac plasma.

U2 - 10.1021/jm0606950

DO - 10.1021/jm0606950

M3 - Comment/Letter to the editor

C2 - 16913694

SN - 0022-2623

VL - 49

SP - 5047

EP - 5050

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

IS - 17

ER -

Low molecular weight activated protein C inhibitors as a potential treatment for hemophilic disorders

Abstract

Access to Document

Fingerprint

Cite this